List of Included studies. by Zahra Tajik (20752452)

Subjects:

Flow chart of the literature search for studies included in meta-analysis. by Zahra Tajik (20752452)

Subjects:

The search strategy in three databases. by Zahra Tajik (20752452)

Subjects:

Summary of meta-analysis results to compare visfatin level before and after NSPT among cases with periodontitis and T2DM. by Zahra Tajik (20752452)

Subjects:

The comparison of GCF visfatin level before and three months after NSPT among cases with periodontitis. by Zahra Tajik (20752452)

Subjects:

A summary of the included study characteristics. by Zahra Tajik (20752452)

Subjects:

NIH score. by Zahra Tajik (20752452)

Subjects:

The comparison of saliva visfatin level before and three months after NSPT among cases with periodontitis. by Zahra Tajik (20752452)

Subjects:

The comparison of GCF visfatin level before and three months after NSPT among cases with periodontitis and T2DM. by Zahra Tajik (20752452)

Subjects:

List of excluded studies. by Zahra Tajik (20752452)

Subjects:

Immunofluorescence staining of p65 NF-κB in Poly (I:C) treated and untreated PK-15 cells at 2, 8, 24 and 48 hours post treatment. by Huan W. Yang (19746645)

Subjects:

Analysis of Tregs from perinatal mice and mixed BM chimeras for transitional and terminal eTreg states. by Erienne G. Norton (9612079)

Targeting of Vps34 reduces B16F10 tumor growth and working model for Vps34-dependent regulation of eTreg transitional heterogeneity and maintenance. by Erienne G. Norton (9612079)

Logistics regression analysis for the associations between decreased kidney function (eGFR < 90 mL/min/1.73 m²) and sex-specific z-scores of anthropometric indices, weig... by Xinyun Chen (6655703)

Uvrag in Tregs is dispensable for establishment of immune tolerance and eTreg accumulation. by Erienne G. Norton (9612079)

Targeting of Vps34 or Atg14, but not Uvrag, in Tregs reduces tumor growth in mouse models. by Erienne G. Norton (9612079)

Vps34 orchestrates Treg function in vivo. by Erienne G. Norton (9612079)

Atg14 deficiency in Tregs induces a type-I-dominant lymphoproliferative disease and cell-intrinsic reductions in eTregs. by Erienne G. Norton (9612079)

Loss of Vps34 reduces Treg suppressive function and is associated with the development of type-I-dominant inflammatory disease. by Erienne G. Norton (9612079)

Vps34 supports Treg maintenance in lymphoid and non-lymphoid tissues. by Erienne G. Norton (9612079)

“…Two-tailed Student <i>t</i> test (<b>A</b>–<b>D</b>, <b>F</b>–<b>I</b>) or Benjamini–Hochberg test (<b>E</b>); NS, not significant. Data are compiled from 15 (<b>A</b>, <b>F</b>), 12 (<b>B</b>), 5 (<b>C</b>, <b>G</b>, <b>I</b>), 6 (<b>D</b>, lung and liver; <b>H</b>), or 2 (<b>D</b>, colon LP) independent experiments. …”